FreeCME

Incorporating Advancements in Monoclonal Antibody Therapeutics into Patient Management Strategies within Dyslipidemia

This CME/CE program addresses scientific advancements in monoclonal antibody therapy and the management of patients with dyslipidemia. The unique educational format of this initiative includes a learner driven, interactive, on-demand, webcast structured as three 20-minute modules that will each be delivered using the unique ArcheMedX Platform. This program aims to arm health care providers with information on disease management, diagnosis, and emergent clinical trial data in order to improve the care administered to patients with dyslipidemia. The interactive set-up of this CME program will provide an optimal learner experience, resulting in greater quality care for patients in practice.

Each module offers:

  • 0.50 AMA PRA Category 1 Credit(s)TM for physicians, per module
  • 0.5 contact hours for pharmacists (0.05 CEUs), per module
  • 0.4 and 0.3 contact hours for nurses (module 1 and 2, 0.4 CE’s; module 3, 0.3 CE’s)

 

Module 1: Guidelines, New Options for LDL Management, and Statin Intolerance

This session is the first in a three part program addressing scientific advancements in monoclonal antibody therapy and the management of patients with dyslipidemia.

Module 2: Clinical Trials Targeting PCSK9 for Treatment of Hyperlipidemia

This session is the second in a three part program addressing current clinical trial data, including efficacy and safety profiles of anti-PCSK9 monoclonal antibodies. The changes in LDL-C in patients as well as methods of administration will be evaluated.

Module 3: Applying Monoclonal Antibodies with Statin Therapy to Optimize Patient Outcomes

This session is the third in a three part program addressing relevant data in regards to developing individualized treatment plans with PCSK9 inhibitor monoclonal antibody therapies. Case-based content for clinical decision making will be provided as well as current challenges in the treatment of familial hypercholesterolemia, including persistently high Lp(a).